Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding:
“Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining forces to build a first-of-its-kind AI co-innovation lab—one that holds the potential to reinvent drug discovery and accelerate life-changing medicines to patients.
By combining our volumes of data and scientific knowledge with NVIDIA’s computational power and model-building expertise—brought together by world-class talent in a startup environment—we’re creating the conditions for breakthroughs that neither company could achieve alone.”
Quoting Eli Lilly and Company’s post:
“How can we make the biggest impact on the future of medicine? By uniting scientists and technologists to speed discovery to solve some of the toughest challenges in human health.
Learn more about our most recent investment.”
Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, shared a post on LinkedIn:
“Today is a watershed moment:
We just announced a billion-dollar bet on AI in drug discovery!
With data generation and compute at this unprecedented scale we will be able to train novel foundation models and realize a true continuous learning loop to drive drug discovery and medicine making like never before.
This joint co-innovation lab between Eli Lilly and Company and NVIDIA follows on top of building the industry’s most powerful supercomputer last year. Most importantly, these are not just a lot of resources that both companies put in, but we are building a truly joint Lilly/NVIDIA team of AI scientists, chemists, biologists and engineers, collocated in a joint facility at the heart of Silicon Valley.
Why now?
We are in the midst of a historic build-out of compute capabilities for AI but most of it is not focused on actually improving the human condition. This changes now! I am deeply convinced, if done right, hAI can help us progress science and find new medicines to effectively lessen human suffering.
Making this dream a reality would not have been possible without the vision of Dave Ricks and Jensen Huang, the effective leadership of Diogo Rau and Kimberly Powell and all the support from Daniel Skovronsky, Lucas Montarce, Andrew Adams and my dear colleagues at Lilly and NVIDIA, Rory Kelleher, Tim Coleman, Mat Torgow, Justin Avanzato, Ajit A. Rajput, Anthony Costa, Nick Merker, Tracy Huang Harrison, Pushkar Ghanekar and so many more.
I am deeply humbled to be part of such and exceptional team.
The future of AI for science is brighter than ever!”
More posts about NVIDIA.
